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Objectives: The efficacy and safety of plerixafor, an antagonist of the CXCR4 receptor, in combination with
G-CSF has been demonstrated in patients suffering from Iymphoma and multiple myeloma (MM) eligible for
autologous haematopoietic stem cell collection. However, different reimbursement criteria have been
applied in different countries to select patients eligible for treatment with plerixafor. The objective of this
observational study was to describe the plerixafor prescription modalities in daily practice in Belgium.
Methods: This open-label, prospective, observational study was conducted in 11 Belgian centres in 114
patients with lymphoma (Hodgkin’s and non-Hodgkin’s lymphoma) or MM who were treated with plerixafor
according to the SmPC between April 2011 and October 2012. Patients included in another clinical trial with
plerixafor were excluded from the study.
Results: The use of plerixafor in patients with MM or lymphoma was effective, with a success rate (defined
as a total yield .26106 CD34z cells/kg) of 77%, and well tolerated (one SAE reported). Optimal collection
(defined as a total yield .46106 CD34z cells/kg) was obtained for 43% of the study population (31% in
lymphoma patients, compared to 61% in patients with MM). The use of plerixafor was in line with the SmPC
and the Belgian reimbursement criteria for all patients.
Conclusion: This study is showing that the use of plerixafor according to Belgian reimbursement criteria
results in similar efficacy and safety as in other centres and countries worldwide.
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Introduction
Intensive chemotherapy followed by autologous stem
cell transplantation is an important treatment mod-
ality for patients suffering from lymphoma or multiple
myeloma (MM).1–3 This strategy is associated with
improved overall survival, event-free and progression-
free survival.4,5 Transplantation of autologous hae-
matopoietic stem cells (HSC) is required for the
recovery from bone marrow aplasia caused by high
dose chemotherapy.6–8 However, autologous trans-
plantation can only be performed if an adequate
autologous graft is available. Transplantation with
stem cells from peripheral blood has largely replaced
transplantation with bone marrow stem cells.
Stem cells can be mobilized to the peripheral blood
by the use of a haematopoietic growth factor such as
Granulocyte Colony Stimulating Factor (G-CSF).
G-CSF can be used with or without mobilizing
chemotherapy. However, these mobilization strate-
gies are not always satisfactory. According to recent
literature data, the proportion of patients for whom
the collection of an adequate graft fails varies from 4
to 48%.1–11 In these papers, an adequate graft was
defined as a graft containing more than 26106 CD34
cells per kg body weight collected in a maximum of 4
to 5 leucapheresis procedures. The failure rate is
Correspondence to: Dominik Selleslag, MD, AZ Sint-Jan Brugge-
Oostende, Afdeling Hematologie, Ruddershove 10, 8000 Brugge,
Belgium. Email: Dominik.Selleslag@azbrugge.be
16
 Acta Clinica Belgica 2015
DOI 10.1179/2295333714Y.0000000077 Acta Clinica Belgica 2015 VOL. 70 NO. 1
higher in elderly patients, in patients previously
treated with myelosuppressive chemotherapy,10,12 in
case of marrow involvement at diagnosis4 and
especially after failure of a previous mobilization
attempt. With the current strategies of mobilization
and remobilization, the risk of remobilization failure
is much higher than for the first attempt: only 30% of
remobilized patients can undergo autologous stem
cell transplantation (HSCT) with the total number of
cells obtained during the first and second attempt.8
Plerixafor, the active substance of MozobilH, is a
bicyclam derivative and is a selective, competitive and
reversible antagonist of the CXCR4 receptor
expressed on HSC. Plerixafor inhibits the binding of
the CXCR4 receptor to its SDF1alpha ligand,
produced by stromal cells. By disrupting the
CXCR4/SDF1alpha axis plerixafor mobilizes HSC
to the peripheral blood, where they can be collected
by apheresis.13 Plerixafor in combination with G-
CSF is approved to improve mobilization of HSC to
the peripheral blood for collection and subsequent
autologous transplantation in patients with lym-
phoma and MM whose cells mobilize poorly.
The efficacy and safety of plerixafor in combina-
tion with G-CSF has been demonstrated in patients
suffering from Non-Hodgkin’s Lymphoma (NHL)
and MM eligible for autologous HSCT. Plerixafor
significantly increases the number of CD34z cells
collected, reduces the number of apheresis procedures
required to collect an adequate number of stem cells,
increases the chance to collect an optimal graft and
reduces the collection failure rate. A significantly
higher number of patients are able to proceed to
autologous HSCT with plerixafor compared with
standard mobilization with G-CSF.13,14 In addition,
plerixafor overcomes mobilization failures in about
70% of patients who had already failed a previous
collection or mobilization attempt.15–18
Worldwide, different criteria are applied to select
patients for treatment with plerixafor. In some
countries, the use of plerixafor is restricted to patients
who need remobilization, while in other countries the
use is less restricted. In Europe, the use of plerixafor
is mainly restricted to known poor mobilizers. In
Belgium, the current reimbursement criteria are as
follows: patients with lymphoma or MM who are
candidates for an autologous HSCT and who are
failing mobilization (less than 10–15 cells CD34z
cells/ml blood mobilized) or who are failing collection
(less than 26106 CD34z cells/kg collected) after G-
CSF administration (10 mg/kg) during at least 4 days
or after chemomobilization with G-CSF. The objec-
tive of this observational study was to describe the
plerixafor prescription modalities in daily practice in
Belgium.
Materials and Methods
This open-label, prospective, multi-centre, observa-
tional study was conducted in Belgium in patients
treated with plerixafor between April 2011 and
October 2012. The study was approved by the
Ethics Committee of the University Hospital of
Leuven (no. B322201110611) and was performed in
compliance with GCP and all local applicable rules
and regulations. The study was conducted in 11
Belgian centres. All patients treated with plerixafor
who gave their written informed consent and for
whom data were available were included in the study.
Patients who were already included in another
clinical trial with plerixafor were excluded from the
study. The following information was recorded:
demographics, current and past treatment, previous
stem cell mobilization attempts, current mobilization
treatment, results of mobilization, and safety. Data
were statistically analyzed in a descriptive manner
(mean, standard deviation and range).
Results
Demographics
In total, 114 patients who were treated with
plerixafor according to the SmPC between April
2011 and October 2012 were included in the study
(Table 1). This corresponded to 77% of the total
number of Belgian patients treated with plerixafor in
the time frame of the study. Of the 114 patients, 46
(40.4%) were treated for MM, while 68 (59.6%)
patients were treated for lymphoma [59 (51.8%)
patients with NHL and 9 (7.9%) with HL].
All patients with lymphoma (HLzNHL) were
previously treated with chemotherapy, compared
with 42 MM-patients (91%). Only 13% of the total
Table 1 Demographic information for patients with myeloma, lymphoma and the entire study population
MM (n546) NHLzHL (n568) Total (n5114)
Gender (M/F) Number (%) 21/25 (46%/54%) 36/32 (53%/47%) 57/57 (50%/50%)
Mean age6SD (range) 62.567.7 56.1615.0 58.7612.9
(in years) (42.9–74.7) (17.6–77.0) (17.6–77.0)
Mean height6SD (range) 165.6627.7 166.6632.4 166.2630.6
(in cm) (157–193) (152–196) (152–196)
Mean weight6SD (range) 72.5616.3 76.9616.7 75.1616.6
(in kg) (45–119) (47–127.7) (45–127.7)
Note: MM, multiple myeloma; NHL, Non-Hodgkin’s lymphoma; HL, Hodgkin’s lymphoma.
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population previously received radiotherapy. More
patients with MM (n54; 9%) had received a prior
stem cell transplant than patients with lymphoma
(n51; 4.4%).
Mobilization history in remobilization patients
In the total population, only 27% of the patients
(n531) were remobilized patients (Table 2). Previous
mobilization was mainly done in steady state using
G-CSF alone (n57; 6.1%) or on the backbone of
therapeutic chemotherapy (n510; 8.8%). Specific
chemotherapy for mobilization purposes was the
least frequently used mobilization regimen (n54;
3.5%). Ten patients (8.8%) had been mobilized with
plerixafor in first line and had failed. They were
included in this registry as remobilization patients. Of
the 31 remobilized patients, 24 (77.5%) underwent
one previous mobilization attempt, while five (16%)
had two attempts and two (6.4%) had more than two
previous mobilization attempts.
In nine of 31 patients, no apheresis had been
performed due to low peripheral blood CD34 counts.
In 21 of 31 patients, apheresis was performed with an
average yield of CD34z cells of 3.226106cells/kg;
seven of these 21 patients had an apheresis yield higher
than 26106 cells/kg. However, these seven patients
were considered as poor mobilizers and mobilized with
plerixafor in the second round of apheresis due to low
pre-apheresis CD34 counts (,15 cells/ml) after at least
4 days of G-CSF or due to insufficient yield for double
transplant in the first apheresis.
Current mobilization procedure for all patients
Specific chemotherapy for mobilization purposes
only was administered in 13.2% of all patients
(n515), with the most frequent use in patients with
MM (Table 3). Overall, 47.8% of the MM patients
(n522) were mobilized with G-CSF and plerixafor
alone, potentially avoiding the side effects of chemo-
mobilization. In lymphoma patients, mobilization
with G-CSF and plerixafor was more frequent (n537;
54.4%) than mobilization with G-CSF/plerixafor and
chemotherapy. Most cases of chemomobilization in
lymphoma were performed in the frame of the
chemotherapeutic treatment of the disease. For the
31 patients who already underwent a previous
mobilization attempt, the most frequently used
mobilization regimen applied the second time was
G-CSF in combination with plerixafor (n518; 58.1%)
(Table 4).
Ninety-six patients (84.2%) received one or two
administrations of plerixafor in the mobilization
regimen (Table 5). Only one patient was treated up
to 4 days with plerixafor. For most patients (n5101;
88.6%), plerixafor was administered in a hospital
setting (hospitalization or day care unit).
Mobilization efficacy
Before mobilization with plerixafor, the mean CD34z
cell count was 10.1616.4 cells/ml. The CD34z cell
count increased 2.78-fold after a first administration of
plerixafor (28.2625.1 cells/ml). For 92 patients (80.7%),
the pre-apheresis CD34z cell count before plerixafor
was lower than 15 cells/ml. Another seven patients
(6.1%) were known as poor mobilizers with a collection
yield in previous mobilization (,26106 cells/kg) or did
not undergo apheresis. For 15 patients (13%; 10
patients in the MM-group and 5 patients in the
lymphoma-group), the pre-apheresis CD34z cell
count before plerixafor was higher than 15 cells/ml.
However, in 11 of them, one or two apheresis sessions
with a collection yield below 26106 cells/kg were
performed after which the mobilization session was
rescued by administration of plerixafor. Two patients
with a high pre-apheresis CD34z cell count were
Table 2 Mobilization history for patients with myeloma, lymphoma and the entire study population
MM (n546) NHLzHL (n568) Total (n5114)
No previous mobilization 36 (78.3%) 47 (69.1%) 83 (72.8%)
Previous mobilization with 10 (21.7%) 21 (30.8%) 31 (27.2%)
G-CSF 4 (8.7%) 3 (4.4%) 7 (6.1%)
G-CSFzmobilization chemotherapy 1 (2.2%) 3 (4.4%) 4 (3.5%)
G-CSFztherapeutic chemotherapy 3 (6.5%) 7 (10.3%) 10 (8.8%)
Other* 2 (2.9%) 8 (11.8%) 10 (8.8%)
Note: MM, multiple myeloma; NHL, non-Hodgkin’s lymphoma; HL, Hodgkin’s lymphoma.
*These 10 patients underwent a previous mobilization session with plerixafor and have been included in this study.
Table 3 Mobilization regimen used in combination with plerixafor for the total population, divided per myeloma and
lymphoma group
MM (n546) NHLzHL (n568) Total (n5114)
G-CSF 22 (47.8%) 37 (54.4%) 59 (51.7%)
G-CSFzmobilization chemotherapy 9 (19.6%) 6 (8.8%) 15 (13.2%)
G-CSFztherapeutic chemotherapy 15 (32.6%) 25 (36.7%) 40 (35.1%)
Note: MM, multiple myeloma; NHL, non-Hodgkin’s lymphoma; HL, Hodgkin’s lymphoma.
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already mobilized with plerixafor a few weeks earlier
and were considered as known poor mobilizers.
Therefore, the use of plerixafor in these patients with
CD34z cell count exceeding 15 cells/ml was also in line
with the reimbursement criteria.
On average, 1.7960.88 apheresis days were per-
formed in the total study population. This was
slightly lower in the lymphoma-group (1.7360.90;
range: 0–4 days) compared with the MM-group
(1.8760.85; range: 0–3 days).
On day 1 of plerixafor administration, 95 patients
(83.3%) went to apheresis and more than or equal to
26106 cells/kg (mean apheresis yield 3.256106 cells/kg)
could be collected in 60% of them. In the total
population, the mean total CD34z cells collected was
4.2863.326106 cells/kg. Collection yields were higher
in the MM-group (5.5863.646106 cells/kg) in compar-
ison with the lymphoma-group (3.3962.766106 cells/
kg). In the total study population, success rate (defined
as total yield §26106 CD34z cells/kg) was 77%. In
first attempt mobilization, this success rate was 82%,
while it was 63% in the group of patients who have been
mobilized at least once. Overall success rate and first
mobilization success rate was higher in patients with
MM than in patients with lymphoma (84 vs 72%, and
88 vs 76%, respectively).
The 10 patients who were mobilized with plerixafor
in the first and second mobilization attempt were
separately analyzed. In all but one of these 10
patients, the apheresis yield of the first mobilization
with plerixafor was ,26106 CD34 cells/kg.
However, in all but one of the 10 patients a
collection of §26106 CD34/kg was possible in the
second mobilization round with plerixafor, demon-
strating that plerixafor can be used successfully in
patients that failed a first mobilization round with
plerixafor.
The relationship between total yield collection and the
pre-plerixafor CD34z cell count is shown in Table 6. In
the group with a pre-plerixafor pre-apheresis CD34z cell
count less than 5 and more than 2 cells/ml, the success
rate, defined as collection yield above 26106 CD34z
cells/kg, was 75.8%. For patients with a pre-plerixafor
pre-apheresis CD34z cell count higher than 10 cells/
ml, success rate with plerixafor was 100%. Analysis of
the relationship between pre-plerixafor CD34zcell
counts and the total yield collected per patient shows a
relatively high success rate (40%) in those patients with
very low pre-plerixafor CD34z cell counts (below 2
cells/ml). Optimal collection, defined as a total collec-
tion yield of 46106 cells/kg, was obtained for 43% of
the total study population (n549) (31% in patients
with lymphoma, compared with 61% in patients with
MM).
Safety
A total of 14 adverse events (AEs) were reported by
seven patients (6.1%). One patient showed an allergic
reaction (including rash, facial oedema and hypoten-
sion), which was classified as a serious adverse event
(moderate grade). Most frequent adverse events were
gastro-intestinal (diarrhoea, nausea and abdominal
pain). Hypotension was reported in two additional
patients (1.7%). Plerixafor was discontinued in three
patients and medication was needed in three patients
to treat the adverse event (allergic reaction and low
blood pressure). All reported events resolved within
24 hours.
Discussion
The population in this observational study is
representative of all patients treated with plerixafor
in Belgium as the participating centres covered 77%
of total sales in Belgium over the study period. A
total of 114 patients with lymphoma or MM under-
going stem cell mobilization were included in the
registry.
Success was defined as a total yield collected over
the complete mobilization session of 26106CD34z
Table 5 Number of administration days of plerixafor for patients with myeloma, lymphoma and the entire study
population
Number of administration days of plerixafor MM (n546) NHLzHL (n568) Total (n5114)
1 23 (50.0%) 29 (42.6%) 52 (45.6%)
2 17 (37.0%) 27 (39.7%) 44 (38.6%)
3 6 (13.0%) 11 (16.2%) 17 (14.9%)
.3 0 (0.0%) 1 (1.5%) 1 (0.9%)
Note: MM, multiple myeloma; NHL, non-Hodgkin’s lymphoma; HL, Hodgkin’s lymphoma.
Table 4 Mobilization regimen used in combination with plerixafor for the remobilization patients, divided per myeloma
and lymphoma group
MM (n521) NHLzHL (n510) Total (n531)
G-CSF 13 (62.0%) 5 (50.0%) 18 (58.1%)
G-CSFzmobilization chemotherapy 0 (0.0%) 1 (10.0%) 1 (3.2%)
G-CSFztherapeutic chemotherapy 8 (38.0%) 4 (40.0%) 12 (38.7%)
Note: MM, multiple myeloma; NHL, non-Hodgkin’s lymphoma; HL, Hodgkin’s lymphoma.
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cells/kg or more. Overall success rate of mobilization
with plerixafor in the difficult to mobilize population
included in this registry was 77%. The success rate
was higher in patients in a first mobilization attempt
(82%) as compared to patients having already
undergone a previous mobilization attempt (63%).
When looking at the information by disease type,
success rate was higher in patients with MM than in
lymphoma patients (84 vs 72%), which corresponds
to earlier observations in the registration phase III
trials for plerixafor.13,14
Analysis of the relationship between pre-plerixafor
CD34zcell counts and the total yield collected per
patient shows a relatively high success rate (40%) in
those patients with very low pre-plerixafor CD34z
cell counts (below 2 cells/ml). Interestingly, the cut-off
value of 10 cells/ml blood correlates with a 100%
success rate with plerixafor.
In general, results observed in a real world context
are often less positive then those observed in a well-
controlled clinical trial context. Efficacy results
reported for plerixafor in clinical trials are indeed
somewhat better than those observed in our registry.
This is not surprising as the population in our registry
was a selected group meeting the reimbursement
criteria for plerixafor in Belgium. These patients by
definition can be classified as patients with mobiliza-
tion difficulties.
In patients with known collection failure in a
previous attempt, Hubel et al.19 reported a success
rate of 73.8% in a median of two apheresis days based
on data from the European Compassionate Use
Program for plerixafor with better results in patients
with MM (success rate 81.6%) than in patients with
NHL (success rate 64.8%). For the Belgian patients
included in this European Compassionate Use
Program, a success rate of 64% in a mean of two
apheresis sessions has been reported,20 which is in line
with the observation in this registry in the group of
patients with known mobilization failure (63%).
Plerixafor use in a first mobilization attempt has
been described by Russell et al.21 who has reported
results of the European multicentre PREDICT trial
in which plerixafor was used in first line in all
mobilization attempts. Success rate was 96% in a
median of 1 day of apheresis (range 1–3). By disease
type, a 98% success rate was observed in patients with
MM and 80% in patients with NHL. The mean fold
increase of CD34z cell counts after one dose of
plerixafor was 2.6. Despite the fact that the popula-
tion enrolled in the Belgian registry was restricted to
difficult to mobilize patients (as defined by the
reimbursement criteria in Belgium), the data observed
in this registry are in line with the PREDICT trial. In
the Belgian registry, the observed success rate of the
first mobilization attempt was 88 and 76.5% in
patients with MM or lymphoma, respectively. Mean
fold increase of CD34z cell count after one dose of
plerixafor in the registry was 2.78, which is very close
to that observed in the PREDICT trial.
Data in patients with low pre-plerixafor CD34z
cell counts after 4 days of G-CSF have been
published recently, based on a post hoc analysis of
the double blind controlled phase III trials for
plerixafor in MM and NHL.22,23 In these publica-
tions, failure rate in the placebo groups (patients
mobilized with G-CSF alone) for patients with low
CD34z cell counts at Day 4 are high. In patients
with MM with less than 15 CD34z cells/ml after
4 days of G-CSF administration, total collection
yield obtained in the G-CSF alone group was below
the minimum target in 22% of the patients.23 It was
below the minimum target in 5% of the patients
mobilized with plerixafor and G-CSF.23 In this
Belgian registry, for 12% of the MM patients a total
yield below target was obtained after first line
mobilization with plerixafor. Per inclusion criteria,
these patients presented with less than 15 CD34z
cells before plerixafor administration. In the post hoc
analysis of the phase III trial in NHL,22 failure rate in
the placebo group of patients with a CD34z cell
count below 15 CD34z cells/ml after 4 days of G-
CSF administration was 59%. The failure rate was
19% in the comparative group with low pre-apheresis
CD34z count mobilized with plerixafor and G-
CSF.22 In the Belgian registry, 23.5% of the patients
Table 6 Total yield CD34z cells collected in relation to pre-plerixafor CD34z cell counts. Collection failure was deﬁned







success, n (%) Total number of patients, n (%)
,2 15 (60.0%) 10 (40.0%) 25 (100%)
2–5 7 (24.1%) 22 (75.8%) 29 (100%)
5–10 4 (15.3%) 22 (84.6%) 26 (100%)
10–15 0 (0%) 19 (100%) 19 (100%)
.15 0 (0%) 14 (100%) 14 (100%)
Total population* 26 (23.0%) 87 (76.9%) 113 (100%)
Note:
*Information is missing for one patient.
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with lymphoma who received plerixafor with a
baseline CD34z count less than 15 cells/ml did not
collect the minimum of 26106cells/kg. In summary,
failure rates with plerixafor mobilization in poor
mobilizers in the Belgian registry compared to those
observed in the post hoc analysis of the phase III trials
are higher (12 vs 5% in MM, 23.5 vs 19% in
lymphoma). This can partially be attributed to the
fact that in the phase III trial no remobilization
patients were included, while 27.2% of the patients in
the registry had already experienced a previous
mobilization attempt.
Analysis of the literature regarding cut-off values
for CD34z cell counts after at least 4 days of
treatment with G-CSF indicates that cut-off values
for pre-plerixafor CD34z cell counts implemented in
some centres in US and EU and defining a group of
‘proven poor mobilizers’ are close to those used in the
Belgian reimbursement criteria.8,24–29 In addition to
decision making based on pre-apheresis CD34z cell
counts, in many centres ‘known poor mobilizers’
(patients with previous mobilization failure, i.e. a
collection yield of less than 26106cells/kg) are treated
with plerixafor. Belgian reimbursement criteria also
include these ‘known poor mobilizers’.
One Serious Adverse Event (allergic reaction to
plerixafor) was reported. Overall, plerixafor was well
tolerated with adverse events (of mild or moderate
intensity) reported in 6% of the patients. AEs were
mainly gastrointestinal. Hypotension as adverse
event was reported in two patients and in the patient
who presented with allergic reaction. These data are
in line with literature data.
Conclusion
The criteria for reimbursed use of plerixafor in
Belgium are comparable with the strategies of use
implemented in different countries and centres world-
wide. Reported efficacy and safety information from
the Belgian registry is in line with the published
results of clinical studies in comparable patient
populations.
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